Drug Profile
Ondansetron sublingual - Benuvia Therapeutics
Alternative Names: Ondansetron sublingual spray - INSYS TherapeuticsLatest Information Update: 29 Feb 2024
Price :
$50
*
At a glance
- Originator INSYS Therapeutics, Inc
- Developer Benuvia Therapeutics
- Class Anti-inflammatories; Antiemetics; Antipsychotics; Carbazoles; Drug withdrawal therapies; Imidazoles; Irritable bowel syndrome therapies; Obesity therapies; Small molecules; Smoking cessation therapies
- Mechanism of Action Serotonin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Chemotherapy-induced nausea and vomiting
Most Recent Events
- 27 Feb 2024 Chromocell Corporation in-licenses ondansetron sublingual from Benuvia Therapeutics
- 27 Feb 2024 Chromocell Corporation plans a clinical trial in 2025
- 23 Mar 2021 Phase II development in Chemotherapy induced nausea and vomiting (Prevention) is ongoing in USA (Sublingual) (Benuvia Therapeutics pipeline, March 2021)